

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

FIG. 1A

PEPTIDE	SEQUENCE	1.00E+03	6.00E+03	1.00E+04	6.00E+04	1.00E+05	6.00E+05	1.00E+06
Thr	X-X-X-X-Thr-X-X-X-X-X-X-Gly	1.02	1.32	0.54	0.34	0.07	0.04	0.02
Ser	X-X-X-X-X-Ser-Thr-X-X-X-X-X-X-Gly	0.11	0.08	0.01	0.00	0.01	0.00	0.00
Threonine* mix	16 phospho-Thr peptide	1.84	1.13	0.40	0.26	0.10	0.07	0.05
Serine* mix	38 phospho-Ser peptide	0.12	0.04	0.02	0.02	0.02	0.01	0.00
AKI-Thr308-P	Ile-Lys-Asp-Gly-Ala-Thr-Met-Lys-Thr-Phe-Gly-Gly-Thr-Pro (SEQ ID NO 1)	1.18	0.65	0.24	0.13	0.03	0.01	0.00
APP1-Thr688-P	Asp-Ala-Met-Lys-Thr-Pro-Lys-Lys-Ala-His-Leu-Ser-Lys-Gly (SEQ ID NO 2)	0.14	0.03	0.01	0.01	0.01	0.01	0.00
C3-P	Asp-Thr-Glu-Lys-Ala-Ala-Thr-Phe-Val-Gly-Thr-Pro-Phe-Gly (SEQ ID NO 3)	1.71	1.13	0.39	0.22	0.03	0.02	0.02
CAK-Thr187-P	His-Gln-Val-Thr-Ala-Thr-Tyr-Ala-Gly (SEQ ID NO 4)	1.77	1.15	0.41	0.27	0.06	0.03	0.01
CAMIV-Thr188-P	His-Gln-Thr-Ile-Lys-Thr-Val-Gly (SEQ ID NO 5)	1.70	1.36	0.63	0.40	0.09	0.05	0.01
CDK2-Thr158-P	Ile-Pro-Gln-Val-Thr-His-Leu-Val-Thr-Leu-Gly (SEQ ID NO 6)	1.02	0.66	0.14	0.08	0.03	0.01	0.01
CDK2-Thr158-P	Gly-Val-Thr-Val-Thr-Thr-His-Gln-Val-Thr-Leu-Gly (SEQ ID NO 7)	1.68	1.70	0.81	0.34	0.09	0.04	0.02
p70S8K-Thr389-P	Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Lys-Val-Phe-Lys-Gly (SEQ ID NO 8)	1.09	1.44	0.62	0.39	0.08	0.04	0.01
PKCalpha-P	Lys-Glu-Thr-His-Met-Gly-Val-Thr-Thr-Ala-Thr-Phe-Gly (SEQ ID NO 9)	1.82	1.63	0.94	0.88	0.18	0.08	0.02
ERK2-P	Asp-His-Thr-Gly-Phe-Leu-Thr-Phe-Thr-Val-Ala-Thr-Ala-Thr-Pro-Gly (SEQ ID NO 10)	1.66	1.18	0.51	0.30	0.07	0.04	0.02
Myc Ser58/62-P	Glu-Leu-Leu-Pro-Thr-Pro-Phe-Lys-Ser-Phe-Ser-Ala-His-Gly (SEQ ID NO 11)	0.11	0.06	0.03	0.02	0.02	0.02	0.02
P38-2P	Leu-Ala-Arg-His-Thr-Lys-Ile-Glu-Ile-Thr-Gly-Val-Thr-Ala-Gly (SEQ ID NO 12)	0.84	0.30	0.08	0.03	0.04	0.04	0.02
UNK-2P	Ser-Phe-Met-Met-Thr-Pro-Tyr-Val-Val-Thr-Ala-Thr-Thr-Ala-Gly (SEQ ID NO 13)	1.49	0.44	0.12	0.07	0.03	0.02	0.02

FIG. 1B

PEPTIDE SEQUENCE	phospho-Thr Reactivity
XXXXXXS*XXXXXX	—
XXXXY*XXXX	—
XXXXXPXS*/T*PXR/KXXX (SEQ ID NO:14)	++
XXXXBSXS*XPXXXX (SEQ ID NO:15)	—
XXXXPSXS*XPXXXX (SEQ ID NO:16)	—
XXXXXPXS*/T*PXXXXX (SEQ ID NO:17)	++
XXXXXPXS/TPXXXXX (SEQ ID NO:18)	—
XXXXXT*XXXXXX	+++
XXXXXXS/TXXXXXX	—
21 phospho-Thr peptides mixture	+++
38 phospho-Ser peptides mixture	—
30 phospho-Tyr peptides mixture	—
NEB LIBRARY	
X-X-X-X-D/E-X-X-S*/T*-X-X-X-X-X-C (SEQ ID NO:19)	+++
X-X-X-X-X-X-S*/T*-D/E-D/E-D/E-X-X-X (SEQ ID NO:20)	++
X-X-X-X-F-X-X-F-S*/T*-F/Y-X-X-X-X-C (SEQ ID NO:21)	+++
X-X-X-X-R/K-X-S*/T*-X-X-X-X-X-X-C (SEQ ID NO:22)	+++
X-X-X-R/K-X-X-S*/T*-X-X-X-X-X-X-C (SEQ ID NO:23)	+++
X-X-X-X-X-X-S*/T*-F/I/M-X-X-X-X-X-C (SEQ ID NO:24)	+++
X-X-X-X-X-X-S*/T*-F/I-X-X-X-X-X-C (SEQ ID NO:25)	+++
X-X-X-X-X-X-S*/T*-P-X-X-X-X-X-X-C (SEQ ID NO:26)	++
X-X-X-X-X-T*-X-X-X-X-X-X-C	+++
X-X-X-X-X-P-X-S*/T*-P-X-X-X-X-X-X-C (SEQ ID NO:27)	++
X-X-X-X-X-X-S/T-X-X-X-X-X-X-C (SEQ ID NO:28)	—
X-X-X-X-X-P-X-S*/T*-P-X-R/K-X-X-X-X-C (SEQ ID NO:29)	++
ANTIBODY REACTIVITY	
+++ very strong	ELISA O.D. > 2
++ strong	1 - 2
+ weak	0.2 - 1
- very little	< 0.2

FIG. 1B

FIG. 1C




FIG. 1D

Fixed Amino Acid	-5-4-3-2-1 X X X X Ser*Thr* X X X X X Fixed AA position relative to phospho-Ser*Thr*							+1+2+3+4+5		
	-4	-3	-2	-1	S*/T*	+1	+2	+3		
Ala	+	+	+	+		+	+	+		+
Cys	+	+	+	+		+	+	+		+
Asp	+	+	+	+		+	+	+		+
Glu	+	+	+	+		+	+	+		+
Phe	+	+	+	+		+	+	+		+
Gly	+	+	+	+		+	+	+		+
His	+	+	+	+		+	+	+		+
Ile	+	+	+	+		+	+	+		+
Lys	+	+	+	+		+	+	+		+
Leu	+	+	+	+		+	+	+		+
Met	+	+	+	+		+	+	+		+
Asn	+	+	+	+		+	+	+		+
Pro	+	+	+	+		+	+	+		+
Gln	+	+	+	+		+	+	+		+
Arg	+	+	+	+		+	+	+		+
Ser	+	+	+	+		+	+	+		+
Thr	+	+	+	+		+	+	+		+
Val	+	+	+	+		+	+	+		+
Trp	+	+	+	+		+	+	+		+
Tyr	+	+	+	+		+	+	+		+

FIG. 2A

PEPTIDE	SEQUENCE	ANTIBODY DILUTIONS					
		1.00E+03	5.00E+03	1.00E+04	5.00E+04	1.00E+05	5.00E+05
PXSP-P	X-X-X-X-X-Pro-X-Ser-Thr-Pro-X-X-X-X-X-Cys (SEQ ID NO 27)	1.82	1.97	1.74	1.40	0.70	0.35
Threonine mix	18 phospho-Thr peptides mix	1.97	1.37	0.87	0.38	0.13	0.07
Ser/Thr	X-X-X-X-X-Ser/Thr-X-X-X-X-X-Cys (SEQ ID NO 28)	0.14	0.03	0.01	0.00	0.00	0.00
RB Thr373-P	Val-Ile-Pro-Pro-His-Thr-Phe-Val-Alg-Thr-Val-Met-Asn-Thr-Cys (SEQ ID NO 30)	2.07	2.17	1.70	1.20	0.48	0.18
MKK3-Thr-P	Ser-Val-Ala-Lys-Thr-Met-Ala-Phe-Lys-Cys (SEQ ID NO 31)	0.08	0.04	0.01	0.00	0.00	0.00
PKCalpha-P	Lys-Glu-His-Met-Met-Ala-Phe-Val-Thr-Thr-Arg-Thr-Phe-Cys (SEQ ID NO 32)	0.05	0.02	0.01	0.00	0.01	0.00
p70 S6K-Thr389	Asn-Gln-Val-Phe-Leu-Phe-Thr-Tyr-Val-Ala-Pro-Lys-Lys-Cys (SEQ ID NO 33)	0.11	0.05	0.01	0.00	0.01	0.00
cdk4-Thr172-P	Arg-Ile-Tyr-Ser-Tyr-Gln-Met-Ala-Leu-Thr-Pro-Val-Val-Lys-Cys (SEQ ID NO 32)	2.07	2.21	2.01	1.55	0.89	0.31

FIG. 2B




FIG. 3A

PEPTIDE	SEQUENCE	ANTIBODY DILUTIONS				
		1.00E+03	5.00E+03	1.00E+04	5.00E+04	5.00E+05
14-3-3 BM-P	X-X-X-X-Arg-Ser-X-Ser-X-Pro-X-X-X-Gly (SEQ ID NO 33)	2.41	2.18	1.49	1.15	0.44
14-3-3 BM	X-X-X-X-Arg-Ser-X-Ser-X-Pro-X-X-X-Gly (SEQ ID NO 34)	0.07	0.03	0.02	0.03	0.02
CDC25-Ser216-P	Gly-Leu-Tyr-Ala-Ser-Pro-Ser-Met-Pro-Glu-Asn-Leu-Asn-Arg-Gly (SEQ ID NO 35)	2.35	2.08	1.49	1.05	0.33
CDC25-Ser216	Gly-Leu-Tyr-Ala-Ser-Pro-Ser-Met-Pro-Glu-Asn-Leu-Asn-Arg-Gly (SEQ ID NO 36)	0.05	0.02	0.03	0.03	0.04
Bad-Ser112-P	Thr-Arg-Ser-Arg-His-Ser-Ser-Tyr-Pro-Ala-Gly-Thr-Glu-Glu-Gly (SEQ ID NO 37)	1.58	0.43	0.10	0.03	0.01
Bad-Ser112	Thr-Arg-Ser-Arg-His-Ser-Ser-Tyr-Pro-Ala-Gly-Thr-Glu-Glu-Gly (SEQ ID NO 38)	0.00	0.00	0.00	0.00	0.00
Bad-Ser136	Phe-Arg-Gly-Arg-Ser-Ala-Ser-Ala-Pro-Pro-Ser-Leu-Trp-Ala-Gly (SEQ ID NO 39)	0.03	0.00	0.00	0.00	0.00
Bad-Ser136-P	Phe-Arg-Gly-Arg-Ser-Arg-Ser-Ala-Pro-Pro-Ser-Leu-Trp-Ala-Gly (SEQ ID NO 40)	3.25	1.88	0.73	0.51	0.07

FIG. 3B




FIG. 4A

PEPTIDE	SEQUENCE	MONOCLONAL ANTIBODIES
		8A9
Ser/ThrPro-P	X-X-X-X-X-Ser/Thr-Pro-X-X-X-X-X-Cys (SEQ ID NO. 26)	1.774
ProXSer/ThrPro-P	X-X-X-X-X-Pro-X-Ser/Thr-Pro-X-X-X-X-X-Cys (SEQ ID NO. 27)	0.924
ProXSer/ThrPro-P	X-X-X-X-X-Pro-X-Ser/Thr-Pro-X-X-X-X-X-Cys (SEQ ID NO. 41)	0.02
ProXSer/ThrProXArg-P	X-X-X-X-X-Pro-X-Ser/Thr-Pro-X-Arg-Lys-X-X-X-Cys (SEQ ID NO. 42)	1.855
Thr-P	X-X-X-X-X-X-Thr-X-X-X-X-X-X-Cys	0
Ser-P	X-X-X-X-X-X-Ser-X-X-X-X-X-X-Cys	0.031
Ser/Thr	X-X-X-X-X-X-Ser/Thr-X-X-X-X-X-X-Cys	0.021
Tyr-P	X-X-X-X-X-X-Tyr-X-X-X-X-X-X-Cys	0.023
Rb (Ser795)-P	Ser-Pro-Tyr-Lys-Phe-Pro-Ser-Ser-Pro-Leu-Arg-Ile-Pro-Gly-Cys (SEQ ID NO. 43)	0.032
Rb (Thr373)-P	Val-Ile-Pro-Pro-His-Thr-Pro-Val-Arg-Thr-Val-Met-Asn-Thr-Cys (SEQ ID NO. 30)	3.336
Rb (Thr373)	Val-Ile-Pro-Pro-His-Thr-Pro-Val-Arg-Thr-Val-Met-Asn-Thr-Cys (SEQ ID NO. 44)	0.02

FIG. 4B




FIG. 5A





FIG. 5B



FIG. 5C



FIG. 5D



004405 11304

Phospho-Akt Substrate Antibody

Production of Motif-Specific Context-Independent Antibodies Using Peptide Libraries as Antigens
Comb, et al
Atty. Docket No: CST-138 CIP2
Sheet 12 of 23




Figure 6: Signal to noise ratio of ELISA readings using Phospho-Akt Substrate Antibody with phospho-peptides of Akt substrates vs. non-phospho-peptides of Akt substrates.



Figure 7: Western analysis of calyculin A-treated A431 cells using Phospho-Akt Substrate Antibody.

- +
calyculin A

Phospho-PKA Substrate Antibody




Figure 8: Signal to noise ratio of ELISA reading using phospho-PKA substrates antibody against peptides have Arginine or Lysine at -3 position.

Phospho-PKA Substrate Antibody



Figure 9: Western analysis of calyculin A-treated A431 cells using Phospho-PKA Substrate Antibody.

- + calyculin A




Figure 10: Western analysis of A431 cell extracts phosphorylated by protein kinase A, ERK2 or CDC2/cyclinA in vitro using Phospho-PKA Substrate Antibody.

+	-	+	+	-	+	-	+
-	-	-	+	-	-	-	-

Cell Extracts
PKI

Phospho-Serine/Threonine Phenylalanine Antibody




Figure 11: Signal to noise ratio of ELISA reading using phospho-Serine/threonine phenylalanine antibody against the peptides surrounded by phenylalanine, tyrosine or tryptophan.



Figure 12: Western analysis of calyculin A-treated A431 cells using phospho-Serine/phenylalanine substates antibody.

-
 +
 calyculin A




Figure 13. Signal to noise ratio of ELISA reading, using a context-independent antibody specific for the phospho-PKC consensus substrate motif, with phospho-PKC substrate containing peptides and nonphospho peptides.




Figure 14. Western blot analysis of WEHI 231 cells or Jurkat cells untreated (-) or treated (+) with TPA, probed with a context-independent antibody specific for the phospho-PKC consensus substrate motif.




Figure 15. Western blot analysis of whole cell lysates of Jurkat cells untreated and treated with PMA (50 ng/ml) and ionomycin (1 μ M) for 20 minutes prior to lysis, using a context-independent antibody specific for the phospho-PKC consensus substrate motif. Proteins were separated by 2D electrophoresis prior to blotting.




Figure 16. Western analysis of whole cell lysates of different cells untreated or treated with peroxynitrite, degraded peroxynitrite or pervanadate using a context-independent antibodies specific for phosphotyrosine (upper), and a polyclonal context-independent antibody specific for nitrotyrosine (lower).




Figure 17. Immunocytochemical staining of NIH/3T3 cells treated with degraded peroxynitrite (control) or peroxynitrite using a polyclonal context-independent antibody specific for nitrotyrosine (brown).




Figure 18. Phosphothreonine-X-arginine motif-specific context-independent antibody ELISAs: Signal to noise ratio of phospho versus nonphospho peptides containing the phospho-threonine-X-arginine motif. (T* denotes phosphorylated threonine.)




Figure 19. Western blot analysis of Jurkat cell extracts untreated (–) and treated (+) with TPA or Calyculin A, using a context-independent antibody specific for the phosphothreonine-X-arginine motif.




Figure 20. Immunohistochemical staining of proteins containing phosphorylated threonine-X-arginine motifs in paraffin-embedded human breast carcinoma, using a context-independent antibody specific for the motif.




Figure 21. Western blot analysis of calyculin A treated A431 cells, using a context-independent antibody specific for the phospho-14-3-3 binding motif #2 (phospho(Ser)-Arg-X-(Tyr/Phe)-X-pSer).




Figure 22. Phospho-ATM/ATR consensus substrate motif-specific, context-independent antibody ELISAs: Signal to noise ratio of phospho versus nonphospho peptides. (S* or T* denote phosphorylated serine or threonine.)




Figure 23. Chk2 transfected and UV treated COS cell extracts immunoprecipitated with Chk2 antibody then detected by Western blotting, using a context-independent antibody specific for phospho-ATM/ATR consensus substrate motif.




Figure 24. Western blot analysis of UV treated COS cells, using a context-independent antibody specific for phospho-ATM/ATR consensus substrate motif.

(SEQ ID NOS:
 132-137)




Figure 25. Phospho-14-3-3 binding motif-specific, context-independent monoclonal antibody ELISAs: Signal to noise ratio of phospho versus nonphospho 14-3-3 binding motif peptides. (T* and S* denote phosphorylated threonine and serine).




Figure 26. Western blot analysis of calyculin A treated A431 cells, using a context-independent antibodies specific for phospho-14-3-3 binding motif #1(left, monoclonal; right, polyclonal).




Figure 27. Phospho-PDK1 docking motif-specific, context-independent monoclonal antibody ELISAs: Signal to noise ratio of phospho versus non-phospho peptides corresponding to potential PDK1 docking motifs. (T* and S* denote phosphorylated threonine and serine.)




Figure 28. Western blot analysis of extracts from A431 cells untreated or treated with 0.1 μ M calyculin A for 30 minutes prior to lysis, using a monoclonal context-independent antibody specific for the phospho-PDK1 docking motif.




Figure 29. Immunoprecipitation of extracts from NIH/3T3 cells untreated or treated with 100 ng/ml of PDGF for 20 minutes prior to lysis, using a monoclonal context-independent antibody specific for phospho-PDK1 docking motif and an antibody specific for Akt, then probed with the PDK1 docking motif monoclonal antibody (upper) and the Akt antibody (lower).